Evidence map›Paper›PMID 20051366›Full record

ReviewCancer prevention research (Philadelphia, Pa.)2010

Translating cyclooxygenase signaling in patch heterozygote mice into a randomized clinical trial in basal cell carcinoma.

Jack L Arbiser

Open access · bronzeAbstract readReviewComment
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer prevention research (Philadelphia, Pa.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. New agents for prevention of ultraviolet-induced nonmelanoma skin cancer.Seminars in cutaneous medicine and surgery · 2011
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Jack L ArbiserDepartment of Dermatology, Emory University School of Medicine, Atlanta Veterans Administration Medical Center, GA 30322, USA. jarbise@emory.edu
Emory University · US

Funding

Cutaneous Hemangiomas and Signal TransductionR01AR047901 · NIAMS · EMORY UNIVERSITY · PI ARBISER, JACK L · 2001 to 2018
$4.3M
Skin Manifestations of Tuberous SclerosisR01AR050727 · NIAMS · EMORY UNIVERSITY · PI ARBISER, JACK L · 2005 to 2009
$1.1M
NIAMS NIH HHS R01 AR02030NIAMS NIH HHS R01 AR047901NIAMS NIH HHS R01 AR050727
6 · The paper itself

Abstract

This different perspective on Tang et al. (beginning on p. 25 in this issue of the journal) discusses the pivotal role of cyclooxygenase (COX) signaling in the pathogenesis of basal cell carcinoma (BCC). These investigators conducted elegant experiments showing increased BCC burden in patch heterozygous mice overexpressing COX-2 in the epidermis. Genetic deletion of COX-1 or COX-2 resulted in a robust decrease in BCC burden in patch heterozygote mice. They then studied pharmacologic COX inhibition in mice and humans with loss of patch, finding a trend in humans toward decreased BCC burden. This finding has implications for public health.

Indexed as

Randomized Controlled Trials as TopicAnimalsAntineoplastic AgentsBasal Cell CarcinomaHeterozygoteHumansMicePatched ReceptorsReceptors, Cell SurfaceSignal TransductionSkin NeoplasmsAntineoplastic AgentsPatched ReceptorsReceptors, Cell Surface

Identifiers

PMID20051366
PMCPMC3154731
OpenAlexW2107393697

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.